MOL0 Stock Chart & Stats
€6.45
€0.00(0.00%)
At close: 4:00 PM EDT
€6.45
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.45 - €6.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.09M
Enterprise Value€8.88M
Total Cash (Recent Filing)€7.26M
Total Debt (Recent Filing)€292.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.13
Shares Outstanding20,385,780
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.68Price Target Upside65.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.18
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressCompleting enrollment in the pivotal MIRACLE trial is a durable development milestone that enables a defined Part A data readout and dose-selection process. Progressing toward broader efficacy evidence can strengthen the regulatory pathway and improve partnering potential if results remain supportive.
Cardiac SafetyThe independently reviewed cardiac-safety analysis supports a potentially meaningful differentiation for Annamycin versus traditional anthracyclines. If confirmed in ongoing development, the absence of observed cardiotoxicity could expand physician adoption and preserve treatment potential in difficult oncology settings.
Intellectual PropertyLong-dated patent protection around a lung-targeted liposomal formulation can support exclusivity and protect future development economics across additional oncology indications. The patent strengthens the company’s intellectual-property position while its lead asset advances through clinical testing.
Bears Say
Pre-Commercial LossesMoleculin remains pre-commercial, with no reported revenue to offset a sizable recurring cost base. Persistent operating losses limit internal funding capacity and leave future financial progress dependent on successful clinical development, commercialization, or new strategic revenue sources.
Cash Burn And Capital ErosionSustained negative cash generation means the business cannot currently fund operations from internally generated resources. Continued burn alongside a materially reduced equity base increases reliance on external capital and can constrain strategic flexibility before the pipeline produces commercial cash flow.
Nasdaq Listing RiskThe Nasdaq minimum-bid deficiency creates an ongoing structural risk to the company’s trading venue and market access. Although a hearing process may delay action, failure to regain compliance could reduce investor access, complicate financing, and weaken the company’s capital-markets flexibility.
Moleculin Biotech News
MOL0 FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was €6.45 and its highest was €6.60 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is €5.09M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Mar 19, 2027 which is in 152 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Aug 14, 2026. The company reported -€1.246 earnings per share for the quarter, beating the consensus estimate of -€1.382 by €0.136.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 20,385,780 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -€1.246 in its last earnings report, beating expectations of -€1.382. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in DE:MOL0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
MOL0 Stock 12 Month Forecast
Average Price Target
€10.68
▲(65.56% Upside)